Department of Pathology, City of Hope National Medical Center, Duarte, CA 91010, USA.
Am J Surg Pathol. 2010 Jul;34(7):1049-57. doi: 10.1097/PAS.0b013e3181e5341a.
Langerhans cell histiocytosis (LCH), also known as histiocytosis X, is a rare human disorder characterized by an abnormal accumulation and/or clonal proliferation of Langerhans cells (LCs) in various body organs. The cellular origin of LCs has been a subject of considerable debate since their discovery. As specialized dendritic cells strategically located in epithelia, LCs are generally considered to be of myeloid origin from the bone marrow, however, recent studies in mice have shown that LCs can be derived from lymphoid-committed CD4 precursors, suggesting a lymphoid origin. In human LCH, concomitant or sequential occurrence of a lymphoid or myeloid malignancy has been occasionally reported, suggesting the presence of lineage plasticity and/or the possibility of transdifferentiation of 2 otherwise morphologically and immunophenotypically different neoplasms. To gain a better understanding of the pathogenesis and cellular origin of human LCH, we retrospectively investigated 46 well-characterized LCH cases to detect clonal rearrangements of T-cell receptor gamma gene (TRG@) and immunoglobulin heavy chain and kappa light chain genes (IGH@/IGK@). The study included 25 males and 21 females, with ages ranging from <1 to 59 years. None (0/46) of the cases had a known history or concurrent B or T-cell lymphoma. Of 46 cases, 30% (14/46) cases had clonal IGH@ (4 cases), IGK@ (5 cases) or TRG@ (9 cases) gene rearrangements, respectively. Interestingly, of the 14 cases with at least one clonal rearrangement of lymphoid receptor genes, 3 LCH cases were shown to have both TRG@ and IGH@/IGK@ gene rearrangements, but failed to express T-cell or B-cell lineage specific or associated markers, suggesting lineage plasticity or infidelity of the neoplasm. Furthermore, all of the 14 cases were negative for t(14;18) by quantitative PCR analysis. In conclusion, our study shows that lymphoid receptor gene rearrangements can be detected in a subset of sporadic LCH cases, suggesting a possible lineage relationship between LCs and lymphoid cells or alternatively, derivation of LCs from lymphoid/myeloid precursors. The results provide genotypic evidence supporting the current notion of lineage plasticity of hematopoietic cells and their associated neoplasms.
朗格汉斯细胞组织细胞增生症(LCH),也称为组织细胞增生症 X,是一种罕见的人类疾病,其特征是各种身体器官中朗格汉斯细胞(LCs)的异常积累和/或克隆性增殖。自 LCs 被发现以来,其细胞起源一直是一个备受争议的话题。作为位于上皮组织中的专门树突状细胞,LCs 通常被认为来自骨髓的髓系,然而,最近在小鼠中的研究表明,LCs 可以从淋巴样定向的 CD4 前体中衍生而来,这表明其具有淋巴样起源。在人类 LCH 中,偶尔会报告同时或先后发生淋巴样或髓样恶性肿瘤,这表明存在谱系可塑性和/或两种形态和免疫表型不同的肿瘤发生转分化的可能性。为了更好地理解人类 LCH 的发病机制和细胞起源,我们回顾性研究了 46 例特征明确的 LCH 病例,以检测 T 细胞受体γ基因(TRG@)和免疫球蛋白重链和κ轻链基因(IGH@/IGK@)的克隆重排。该研究包括 25 名男性和 21 名女性,年龄从<1 岁到 59 岁不等。46 例患者中无(0/46)例有已知病史或同时发生 B 或 T 细胞淋巴瘤。在 46 例患者中,分别有 30%(14/46)例存在克隆性 IGH@(4 例)、IGK@(5 例)或 TRG@(9 例)基因重排。有趣的是,在 14 例至少有一种淋巴受体基因克隆重排的病例中,有 3 例 LCH 病例同时存在 TRG@和 IGH@/IGK@基因重排,但未能表达 T 细胞或 B 细胞谱系特异性或相关标志物,提示谱系可塑性或肿瘤的不准确性。此外,所有 14 例病例的定量 PCR 分析均为 t(14;18)阴性。总之,我们的研究表明,在一些散发性 LCH 病例中可以检测到淋巴受体基因重排,这表明 LCs 与淋巴样细胞之间可能存在谱系关系,或者 LCs 可能来自淋巴样/髓样前体。这些结果提供了支持造血细胞及其相关肿瘤谱系可塑性的基因型证据。